NCT05789394View on ClinicalTrials.gov

Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 16, 2023

Primary Completion Date

July 24, 2025

Study Completion Date

July 24, 2025

Conditions
Recurrent Glioblastoma, IDH-WildtypeRecurrent Astrocytoma, IDH-Mutant, Grade 4Astrocytoma, Grade IV
Interventions
BIOLOGICAL

Allogeneic Adipose-derived Mesenchymal Stem Cells

Receive IT

PROCEDURE

Biospecimen Collection

Undergo blood and tissue sample collection

PROCEDURE

Craniotomy

Undergo craniotomy

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Ommaya Reservoir Tap

Undergo Ommaya reservoir placement for collection of CSF

Trial Locations (1)

32224-9980

RECRUITING

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT05789394 - Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy | Biotech Hunter | Biotech Hunter